Hematology-Oncology Consultants
Hematology-Oncology Consultants was paid $3.50M by Medicaid between Jan 2018 and Nov 2024, across 38 billing codes. Its largest line is Q5127, Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg — 17% of everything it billed.
33Billing provider infoHEMATOLOGY-ONCOLOGY CONSULTANTS
HEMET, CA 92543
HEMET, CA 92543
33aNPI1639109457assigned 07/04/2006
33bProvider typeSpecialist
28Total paid$3.50M
24GClaims73,497
24DCodes billed38
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#70 of 1,230
Median peer was paid$51K
This provider vs. median68×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,877 | $227K | |
| 2019 | 10,758 | $300K | |
| 2020 | 10,817 | $289K | |
| 2021 | 10,971 | $556K | |
| 2022 | 11,182 | $420K | |
| 2023 | 12,824 | $955K | |
| 2024incomplete | 9,068 | $750K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | 17% | 177 | 142 | $581K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 17,972 | 16,245 | $428K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 12% | 603 | 480 | $413K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 7.1% | 95 | 80 | $247K |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 6.8% | 66 | 55 | $236K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 5.7% | 1,483 | 903 | $200K |
| 96375 | Therapeutic injection; each additional sequential IV push | 5.5% | 7,485 | 5,440 | $194K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 5.0% | 8,800 | 6,536 | $174K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.5% | 14,174 | 8,721 | $159K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.3% | 3,396 | 2,813 | $152K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 3.9% | 2,802 | 2,014 | $135K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 3.6% | 408 | 320 | $126K |
26 more codes
| 99205 | Prolong outpt/office vis | 2.7% | 1,420 | $95K |
| J3590 | Unclassified biologics | 1.7% | 17 | $59K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 1.4% | 21 | $50K |
| 96417 | 1.2% | 1,598 | $42K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 1.2% | 338 | $41K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,091 | $35K |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | <1% | 57 | $29K |
| 96367 | <1% | 853 | $26K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 422 | $17K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 591 | $16K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 76 | $14K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,066 | $11K |
| J2820 | Injection, sargramostim (gm-csf), 50 mcg | <1% | 29 | $8K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,536 | $3K |
| 96415 | <1% | 111 | $2K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 36 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 25 | $1K |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 87 | $1K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 40 | $882.89 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 35 | $449.49 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 74 | $240.48 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 221 | $239.28 |
| 96411 | <1% | 14 | $213.36 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 31 | $166.24 |
| 36415 | Collection of venous blood by venipuncture | 0% | 232 | $0.00 |
| 99497 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHINKE, STANLEY (PRESIDENT)